Targets for Current Pharmacologic Therapy in Cholesterol Gallstone Disease - 22/08/11

Résumé |
Gallstone disease is a frequent condition throughout the world and, cholesterol stones are the most frequent form in Western countries. The standard treatment of symptomatic gallstone subjects is laparoscopic cholecystectomy. The selection of patients amenable for nonsurgical, medical therapy is of key importance; a careful analysis should consider the natural history of the disease and the overall costs of therapy. Only patients with mild symptoms and small, uncalcified cholesterol gallstones in a functioning gallbladder with a patent cystic duct are considered for oral litholysis by hydrophilic ursodeoxycholic acid, in the hope of achieving cholesterol desaturation of bile and progressive stone dissolution. Recent studies have raised the possibility that cholesterol-lowering agents that inhibit hepatic cholesterol synthesis (statins) or intestinal cholesterol absorption (ezetimibe), or drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis, may offer, alone or in combination, additional medical therapeutic tools for treating cholesterol gallstones. Recent perspectives on medical treatment of cholesterol gallstone disease are discussed in this article.
Le texte complet de cet article est disponible en PDF.Keywords : Bile salts, Cholesterol absorption, Ezetimibe, Gallbladder, Nuclear receptors, Statins
Plan
| This work was supported in part by research grants from the Italian Ministry of University and Research (FIRB 2003 RBAU01RANB002), the Italian National Research Council (CNR) (short-term mobility grant 2005), the University of Bari (grants ORBA09XZZT, ORBA08YHKX) (PP), and from the National Institutes of Health (US Public Health Service) (research grants DK54012 and DK73917) (DQ-HW). |
Vol 39 - N° 2
P. 245-264 - juin 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
